[CAS NO. 104227-87-4] Famciclovir

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [104227-87-4]

Catelog

HY-17426

Brand

MCE

CAS

104227-87-4

DESCRIPTION [104227-87-4]

Overview

MDL	MFCD00866964
Molecular Weight	321.33
Molecular Formula	C14H19N5O4
SMILES	NC1=NC=C2N=CN(CCC(COC(C)=O)COC(C)=O)C2=N1

For research use only. We do not sell to patients.

Summary

Famciclovir (BRL 42810) is an orally active nucleoside analogue. Famciclovir is an antiviral agent with potent activities against HBV , HSV and VZV. Famciclovir can be used for the research of herpesvirus infection ^[1] .

In Vitro

Famciclovir metabolizes into BRL 42359 by deacetylation and then oxidizes to penciclovir ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Famciclovir (50-400 mg/kg; p.o. three times per day for total 10 doses) effectively cures necrotic hepatitis mice ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Four- to five-week-old Balb/c mice with HSV-1 infection ^[1]
Dosage:	50, 100, 200 and 400 mg/kg
Administration:	Oral gavage; 50-400 mg/kg per day divided into three doses given every 8 h; for total 10 doses
Result:	Significantly reduced the incidence of hepatitis with a dose of 50 mg/kg per day, and could not isolated infectious virus from the doses of 50 and 100 mg/kg treatment group.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01281007	EMS	GENITAL HERPES	July 2012	Phase 3
NCT03120962	Second Affiliated Hospital, School of Medicine, Zhejiang University	Herpes Zoster\|Post-herpetic Neuralgia	May 2017	Not Applicable
NCT05283551	Queen Mary University of London	Multiple Sclerosis	November 25, 2020	Phase 2
NCT01321502	Roxane Laboratories\|West-Ward Pharmaceutical	Herpes	July 2007	Not Applicable
NCT00098059	Novartis Pharmaceuticals\|Novartis	Herpes Simplex	February 2005	Phase 3
NCT00834444	Teva Pharmaceuticals USA	Healthy	August 2004	Phase 1
NCT00171990	Novartis	Recurrent Genital Herpes	January 2003	Phase 3
NCT01526408	House Research Institute\|House Clinic, Inc.	Meniere´s Disease	December 2011	Phase 3
NCT01321515	Roxane Laboratories\|West-Ward Pharmaceutical	Herpes	July 2007	Not Applicable
NCT00248144	Novartis	Recurrent Herpes Labialis	October 2003	Phase 4
NCT00129818	Novartis	Genital Herpes	July 2004	Phase 4
NCT00448227	Novartis	Herpes Simplex	October 2007	Phase 2
NCT01327144	EMS	Herpes Zoster	June 2012	Phase 3
NCT00098046	Novartis	Chickenpox\|Herpes Zoster	July 2005	Phase 3
NCT00306787	Novartis Pharmaceuticals\|Novartis	Genital Herpes	March 2006	Phase 3
NCT00477334	Novartis	Genital Herpes	June 2007	Phase 4
NCT00834431	Teva Pharmaceuticals USA	Healthy	August 2004	Phase 1
NCT00219310	Novartis	Recurrent Genital Herpes (RGH)	June 2003	Phase 4
NCT00878072	Novartis Pharmaceuticals\|Novartis	Herpes Labialis	March 25, 2009	Phase 2\|Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 311.21 mM )

H ₂ O : 50 mg/mL ( 155.60 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1121 mL	15.5603 mL	31.1207 mL
5 mM	0.6224 mL	3.1121 mL	6.2241 mL
10 mM	0.3112 mL	1.5560 mL	3.1121 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 120 mg/mL (373.45 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (7.78 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (7.78 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (7.78 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, 1,3-diacetate

1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, diacetate (ester)

Famciclovir

BRL 42810

Famvir

FCV

9-[4-Acetoxy-3-(acetoxymethyl)butyl]-2-aminopurine

9-[4-Acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine

Famcyclovir

Famcivir

Famtrex

Fanxiluowei

[2-(Acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate

2-[(Acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate